Treatment of chronic hepatitis C

Minerva Gastroenterologica e Dietologica

Volumn 50, Issue 1, 2004, Pages 29-36

  Marcellin, P ^a   Asselah, T ^a   Ripault, M P ^a   Boyer, N ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Hepatitis C, drug therapy; Liver; Liver transplantation

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; DNA POLYMERASE; ENZYME INHIBITOR; HELICASE; HEPATITIS C VACCINE; NEW DRUG; PARACETAMOL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER NECROSIS; LIVER TRANSPLANTATION; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEUTROPENIA; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; TERATOGENICITY; THYROID DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD;

HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 2442576858     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
2. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31 Suppl 1:9-16.
3. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;226:347-56.
4. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315: 1575-8.
5. EASL International Consensus Conference on Hepatitis C. Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
6. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
7. Lindsay KL, Trépo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
8. Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
9. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
10. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon α-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of the treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
11. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998;282:103-7.
12. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996;124:1058-60.
13. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long term histologic improvement and disappearance of intra hepatic HCV RNA after alpha interferon therapy in patients with chronic hepatitis C. Ann Intern Med 1997;127:875-81.
14. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
15. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19 Suppl 1:25-33.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-32.
17. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
18. French Consensus Conference Treatment of Hepatitis C. Guidelines. Gastroenterol Clin Biol 2002;26:B312-20.
19. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003;52: Issue 12.
20. National Institutes of Health consensus Development Conference Statement: management of Hepatitis C: 2002. Hepatology 2002;36 Suppl 1:S3-21.
21. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000;32:630-4.
22. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-5.
23. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
24. Marcellin P, Lévy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997;26 Suppl 1:133S-7.
25. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology 2002;36 5 Suppl 1:S195-200.
26. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
27. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M et al. The influence of junam immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
28. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36 (5 Suppl 1): S201-9.
29. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619-25.
30. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J et al. Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26: 500-4.
31. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepat 1999;6:435-43.
32. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-23.
33. Foster GR. Hepatitis C virus infection: side effects and quality of life. J Hepatol 1999;31 Suppl 1:250-4.
34. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 3 Suppl 1:112S-21.
35. Gervais A, Boyer B, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf 2001;24:375-84.
36. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36 (5 Suppl 1):S35-46.
37. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36 (5 Suppl 1):S47-56.
38. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 (1 Suppl):98-112.
39. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002;36 (5 Suppl 1):S245-52.
40. Abrignani S, Houghton M, Hsu HH. Perspective for a vaccine against hepatitis C virus. J Hepatol 1999;31: 259-63.